Alpine Immune Sciences Inc
ALPN
ALPN was delisted on the 17th of May, 2024.
53 hedge funds and large institutions have $257M invested in Alpine Immune Sciences Inc in 2021 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 21 increasing their positions, 9 reducing their positions, and 4 closing their positions.
225% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 4
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
133% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 9
57% more capital invested
Capital invested by funds: $164M → $257M (+$93.6M)
20% more funds holding
Funds holding: 44 → 53 (+9)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
+$8.61M |
| 2 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$2.85M |
| 3 |
BlackRock
New York
|
+$2.24M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.45M |
| 5 |
Walleye Capital
New York
|
+$1.36M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$7.27M |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$1.19M |
| 3 |
Wells Fargo
San Francisco,
California
|
-$563K |
| 4 |
LRIA
Leonard Rickey Investment Advisors
Yakima,
Washington
|
-$182K |
| 5 |
HS
HighVista Strategies
Boston,
Massachusetts
|
-$152K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIP
51
Ameritas Investment Partners
Lincoln,
Nebraska
| $13K | – | – | – |
|
|
TRCT
52
Tower Research Capital (TRC)
New York
| $11K | -$14.7K | -1,183 | -60% |
|
53
Daiwa Securities Group
Tokyo,
Japan
| $1K | +$1.05K | +85 | New |
|
|
DCM
54
DAFNA Capital Management
Los Angeles,
California
| – | -$1.19M | -111,501 | Closed |
|
|
LRIA
55
Leonard Rickey Investment Advisors
Yakima,
Washington
| – | -$182K | -17,013 | Closed |
|
|
HS
56
HighVista Strategies
Boston,
Massachusetts
| – | -$152K | -14,268 | Closed |
|
|
EC
57
EcoR1 Capital
San Francisco,
California
| – | -$75K | -7,001 | Closed |
|
ALPN Hedge Fund Activity: Q4 2021 in Review
53 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Alpine Immune Sciences Inc (ALPN) for Q4 2021, worth a combined $257M — up 57% from $164M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new ALPN positions and 4 closed out — a net gain of 9 holders — while 21 added to existing stakes and 9 trimmed.
The largest buyer was Logos Global Management, adding an estimated $8.61M. The largest seller was Avidity Partners Management, cutting an estimated $7.27M.
- 53 institutional investors held Alpine Immune Sciences Inc (ALPN) as of Q4 2021, up from 44 in Q3 2021.
- Funds reported $257M of Alpine Immune Sciences Inc stock for Q4 2021, up 57% quarter-over-quarter.
- 13 funds opened new Alpine Immune Sciences Inc positions in Q4 2021 and 4 closed out, a net change of +9 holders.
- The largest Alpine Immune Sciences Inc buyer in Q4 2021 was Logos Global Management, an estimated $8.61M added.
- The largest Alpine Immune Sciences Inc seller in Q4 2021 was Avidity Partners Management, an estimated $7.27M sold.
Based on aggregated 13F filings for Q4 2021.